These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11858871)

  • 1. Evidence based vaccinology.
    Nalin DR
    Vaccine; 2002 Feb; 20(11-12):1624-30. PubMed ID: 11858871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].
    Pfleiderer M; Wichmann O
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.
    Black S
    Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine provision: Delivering sustained & widespread use.
    Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
    Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why is evidence-based medicine so harsh on vaccines? An exploration of the method and its natural biases.
    Jacobson RM; Targonski PV; Poland GA
    Vaccine; 2007 Apr; 25(16):3165-9. PubMed ID: 17292516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine Development: From Laboratory to Policy.
    Park HS; Samuels EL; Bocchini JA
    Pediatr Ann; 2020 Dec; 49(12):e509-e515. PubMed ID: 33290568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of vaccines: strengthening the science base.
    Milstien JB
    J Public Health Policy; 2004; 25(2):173-89; discussion 190-6. PubMed ID: 15255384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
    Lopalco PL; DeStefano F
    Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
    Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF
    Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The public health value of vaccines beyond efficacy: methods, measures and outcomes.
    Wilder-Smith A; Longini I; Zuber PL; Bärnighausen T; Edmunds WJ; Dean N; Spicher VM; Benissa MR; Gessner BD
    BMC Med; 2017 Jul; 15(1):138. PubMed ID: 28743299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure concept.
    Rustomjee R; Lockhart S; Shea J; Fourie PB; Hindle Z; Steel G; Hussey G; Ginsberg A; Brennan MJ
    Tuberculosis (Edinb); 2014 Mar; 94(2):178-82. PubMed ID: 24360811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: the scientific basis of regulatory expectations pre- and post-licensure.
    Wood D; Shin JH; Duval B; Schmitt HJ
    Vaccine; 2006 Aug; 24 Suppl 3():S3/187-92. PubMed ID: 16950006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.